Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. - Wikidata - awgldk - TriplyDB

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

http://www.wikidata.org/entity/Q37154802

about

Beyond glycemic control: treating the entire type 2 diabetes disorder.The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.Liraglutide: a review of its use in the management of type 2 diabetes mellitus.GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.Cost effectiveness of liraglutide in type II diabetes: a systematic review.Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.

P2860

Q37612693-AEA5B2E4-65FA-4C74-A928-F09A0A9234E8 Q37641333-0A24E255-0C73-4510-8553-02589B995D2E Q37872358-A0ECC3A6-D731-4BB4-86A0-216E3C376BF9 Q37956408-F8659288-405B-47A6-889D-4F1BE37FA06A Q38002008-3787C257-95F3-4652-B077-A76428F74470 Q38232870-74178E5A-FEA1-4C25-B378-D2FA5DE8CC01 Q39548089-B94855C9-DAA5-4A2C-A164-20B7A2367F16 Q41267217-7076BBDE-8B48-4994-8367-BB06B2BB6FBA

P2860

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

http://www.wikidata.org/entity/Q37154802

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@en

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@nl

type

label

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@en

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@nl

prefLabel

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@en

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@nl

P1433

Q37154802-5005ABE8-183D-4627-81F5-6C9DD55CDCC5

P1476

Q37154802-EA4F197E-37E7-43CA-97B4-078948DA71FD

P2093

Q37154802-4F105F0C-B814-4C67-A3E7-942FE1B7EC84

Q37154802-656AAE35-EAFB-4FD2-B191-4C0F05E72E72

Q37154802-9156BB48-D33B-4750-BB49-B630874DA102

Q37154802-B3DCCE0A-F302-47A9-945A-6783A76AA9B6

P2860

Q37154802-12E29AB9-C71B-4601-934F-47E691860125

Q37154802-15470831-0751-4060-AA80-E039C392C2A5

Q37154802-1AA550B7-49AD-48DA-A0A7-5CB2C823C645

Q37154802-1B455C33-EE2F-4719-9E78-0A3BC1AC0055

Q37154802-26DD3CF0-2B8F-44D4-8DBF-8D9A10262CB6

Q37154802-3F52274C-FAB6-4BD7-BB64-B40E35BBE6A8

Q37154802-4A8CC28A-FE82-4550-AE7D-B8ECABFA6ED7

Q37154802-4DCDD3C9-BA41-4955-AAF9-475C17D17D31

Q37154802-4DF5D0E6-1E7C-470C-ACFD-BEF368B5F82D

Q37154802-51D7B77F-81FE-4518-8E11-410956483BE3

P2888

Q37154802-D89C9666-5F48-474B-AB66-5B8325C82AB8

P304

Q37154802-85A5C9C5-F90E-4024-A073-D864E38722DA

P31

Q37154802-90826284-35D0-425B-BDBD-75C29EDB0279

P356

Q37154802-1ADA4FEB-92F4-4118-A53B-A7FFE555D5B9

P407

Q37154802-70986124-96F7-4B22-A25D-5DE2B7D96371

P478

Q37154802-DC054E90-D89B-4C45-8F20-0CBEE6507108

P50

Q37154802-813A6955-7B49-4FCF-92D2-44320D69A267

P577

Q37154802-736E18F5-D59C-450E-9665-D71BEAF3A116

P5875

Q37154802-1E7DE61C-C1A9-4163-B8E5-F6681848B0D8

P6179

Q37154802-0EACE3DF-C92F-4C42-B76C-98A9C811A3D4

P698

Q37154802-4C3FF4FB-27CA-4F5D-B469-3F5EDF47ECFD

P921

Q37154802-B3D0181B-A3D2-45F3-8B9D-540B2B668604

P932

Q37154802-FDF0875F-D410-4DE7-A978-6FAEF0D0E54B

P356

P1433

Cardiovascular Diabetology

P1476

Long-term outcomes in patients ...... liraglutide or rosiglitazone.

@en

P2093

Chris Conner

http://www.w3.org/2001/XMLSchema#string

Lawrence Blonde

http://www.w3.org/2001/XMLSchema#string

Mette Hammer

http://www.w3.org/2001/XMLSchema#string

Sean D Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

Patient perceptions of quality of life with diabetes-related complications and treatments

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Glucose control and vascular complications in veterans with type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

P2888

P304

12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-8-12

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Alfonso-Cristancho

P577

2009-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24042987

http://www.w3.org/2001/XMLSchema#string

P6179

1053109741

http://www.w3.org/2001/XMLSchema#string

P698

19245711

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2667489

http://www.w3.org/2001/XMLSchema#string